IFP Advisors’s Telomir Pharmaceuticals TELO Stock Holding History

IFP Advisors’s Portfolio TELO Stock Details TELO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-3,000	Closed	-$3.99K	–	5185
2025 Q4	$3.99K	Buy	+3,000	New	+$4.33K	﹤0.01%	3524

Other funds holding TELO

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

SEM

Suncoast Equity Management Tampa, Florida $833M AUM 11.9% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

WIA

World Investment Advisors Santa Barbara, California $6.2B AUM 19.68% 1-Year Est. Return

IFP Advisors's TELO Position: Q1 2026 in Review

IFP Advisors sold out of Telomir Pharmaceuticals (TELO) in Q1 2026, closing a stake of 3,000 shares — an estimated $3.99K sold.

IFP Advisors first reported a position in TELO in Q4 2025 and held it in 1 quarter. The position peaked at $3.99K in Q4 2025. 27 funds tracked by Wall St. Rank hold TELO as of Q1 2026.

IFP Advisors reported no remaining Telomir Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
IFP Advisors sold 3,000 Telomir Pharmaceuticals shares in Q1 2026, an estimated $3.99K.
IFP Advisors first reported a position in Telomir Pharmaceuticals in Q4 2025 and held it in 1 quarter.
IFP Advisors's Telomir Pharmaceuticals position peaked at $3.99K in Q4 2025.
27 funds tracked by Wall St. Rank held Telomir Pharmaceuticals as of Q1 2026.

Based on IFP Advisors's 13F filing for Q1 2026, filed 13 Apr 2026.